Mylan Weighs "Big Bang Or Phased" Products Rollout In India; Significant Workforce Additions Planned
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - On a trip to India, Mylan Inc. CEO and Chairman Robert Coury praised the "voluminous contributions" of Indian arm Matrix Laboratories Ltd. in Mylan's global-scale vertical integration drive, but also announced that the company would rebrand Matrix as Mylan as it moves forward with launching Mylan products in India
You may also be interested in...
Mylan’s India Shopping Spree Is Aimed At Doubling Global Manufacturing Capacity
With two manufacturing units under its belt in the past few months, Mylan may not be done acquiring assets in India.
Mylan Nears Launch Of India Commercial Ops With Push In Anti-HIV Drugs
The world’s third-largest generics firm may have to acquire mid-sized drug units for wider impact
Mylan Chairman Robert Coury On Lipitor's Future and India/Japan Expansion: An Interview With PharmAsia News
Mylan Inc. CEO Robert J. Coury demonstrated his ability to be a trendsetter when Mylan acquired Matrix Laboratories in 2007 at the highest value - at the time - for an India pharmaceutical company. Though doubted for that move and the next - of buying Merck KGaA's generics business for $6.8 billion, Coury now boasts of establishing a global generics footprint with a one-of-a-kind vertically integrated platform to build maximum operational efficiencies.